Cholesterol Management in Theory and Practice
- 16 December 1997
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 96 (12) , 4424-4430
Abstract
The preponderance of evidence confirms the importance of aggressive lipid modification in patients at risk for coronary heart disease (CHD). However, data suggest that this information is underimplemented in the clinical setting, even in patients with existing CHD, in whom the greatest benefit of such treatment has been shown. The fact that many practitioners do not pursue a proven treatment strategy in patients who qualify must be redressed through education and reinforcement of existing recommendations. In the present review, the current clinical and mechanistic understanding of the benefit of aggressive lipid management is summarized, with a focus on the clinical implications of recent findings. These include growing public awareness of cholesterol as a modifiable CHD risk factor, recommendations for earlier and more aggressive intervention in patients with existing disease, and discussion of the cost-effectiveness of lipid-regulating therapy. Despite the secular trend of declining CHD morbidity and mortality rates in recent years, CHD remains the leading cause of death in both men and women in the United States. It is imperative to prevent any reduction in public focus on primary and secondary prevention.Keywords
This publication has 34 references indexed in Scilit:
- EditorialThe American Journal of Cardiology, 1996
- Cost-Effectiveness of Pravastatin in Secondary Prevention of Coronary Artery Disease**This study was supported by Bristol-Myers Squibb, Plainsboro, New Jersey.The American Journal of Cardiology, 1996
- Cholesterol and recurrent events: A secondary prevention trial for normolipidemic patientsThe American Journal of Cardiology, 1995
- The influence of pretreatment lew density lipoprotein cholesterol concentrations on the effect of hypocholesterolemic therapy on coronary atherosclerosis in angiographic trialsThe American Journal of Cardiology, 1995
- Letters to the editorClinical Therapeutics, 1995
- Baseline characteristics in the Cholesterol and Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levelsThe American Journal of Cardiology, 1995
- Cost-effectiveness analysis in heart disease, part II: Preventive therapiesProgress in Cardiovascular Diseases, 1995
- Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiographyThe American Journal of Cardiology, 1992
- HMG CoA reductase inhibitorsCurrent Opinion in Lipidology, 1991
- Angiographic progression of coronary artery disease and the development of myocardial infarctionJACC, 1988